V CompBrief BY VELARION

Chief Medical and Development Officer · Kyverna Therapeutics, Inc. (KYTX)

Naji Gehchan

FY2025 is the first fiscal year CompBrief holds for Naji Gehchan as a named executive officer of Kyverna Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$2,085,173

1st of 3 named executive officers at Kyverna Therapeutics by FY2025 total.

3 named officers on file for Kyverna Therapeutics, FY2025

See an example →

What this number hides

The filing gives the total. Kyverna Therapeutics’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how Kyverna Therapeutics’s whole pay program stands against its peers

  • Kyverna Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KYTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 13, 2026 (DEF 14A).

Free

Get Naji Gehchan’s full pay file as a PDF — free

More than this page: up to 10 years of Naji’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Naji Gehchan and every company like it: Velarion Intel, free for 3 days, no card →

Naji Gehchan compensation by year

Kyverna Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Kyverna Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$481,667
Bonus$250,000
Stock awards$0
Option awards$1,110,100
Non-equity incentive$238,406
Pension and deferred compensation$0
All other$5,000
Total$2,085,173

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kyverna Therapeutics, Inc. DEF 14A filed April 13, 2026, accession 0001193125-26-152835, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kyverna Therapeutics, Inc. filed document, accession 0001193125-26-152835. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option425,000—$3.29

Per the Outstanding Equity Awards at Fiscal Year-End table in Kyverna Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Kyverna Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Naji Gehchan · this pageChief Medical and Development Officer$2,085,173
Warner BiddleChief Executive Officer$1,814,980
Marc GrassoChief Financial Officer$1,663,536

Naji Gehchan's compensation dossier, Kyverna Therapeutics

You have read Naji Gehchan's totals and holdings. The dossier adds each equity grant Kyverna Therapeutics disclosed for Naji Gehchan and Kyverna Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full Kyverna Therapeutics compensation record

free company brief
Kyverna Therapeutics, Inc. (KYTX) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within Kyverna Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Kyverna Therapeutics's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kyverna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order KYTX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Naji Gehchan's compensation dossier